Updated treatment guideline for hormone therapy in postmenopausal women
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권대휘 | - |
dc.contributor.author | 신정호 | - |
dc.date.available | 2020-11-02T06:48:56Z | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.issn | 2093-5951 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2685 | - |
dc.description.abstract | Since menopause hormone therapy was first introduced, it has been widely used worldwide as the most effective treatment for vasomotor symptoms in menopausal women and for genitourinary syndrome of menopause. Menopause hormone therapy has been shown to prevent bone loss and fracture, but it may additionally offer various benefits for numerous other symptoms. The benefit-to-risk ratio of menopause hormone therapy is most favorable for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications. Longer durations of therapy should be limited to patients with documented indications, such as persistent vasomotor symptoms or bone loss. For genitourinary syndrome of menopause, low-dose vaginal estrogen therapy or other therapies are recommended. Tibolone is a synthetic steroid that provides a therapeutic effect in the treatment of menopausal symptoms. © Korean Medical Association | - |
dc.format.extent | 5 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | Korean Medical Association | - |
dc.title | Updated treatment guideline for hormone therapy in postmenopausal women | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5124/jkma.2019.62.3.145 | - |
dc.identifier.scopusid | 2-s2.0-85065479646 | - |
dc.identifier.wosid | 000461763300003 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Medical Association, v.62, no.3, pp 145 - 149 | - |
dc.citation.title | Journal of the Korean Medical Association | - |
dc.citation.volume | 62 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 145 | - |
dc.citation.endPage | 149 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002446911 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | estrogen | - |
dc.subject.keywordPlus | tibolone | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | bone atrophy | - |
dc.subject.keywordPlus | estrogen therapy | - |
dc.subject.keywordPlus | hormonal therapy | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | menopausal syndrome | - |
dc.subject.keywordPlus | postmenopause | - |
dc.subject.keywordPlus | practice guideline | - |
dc.subject.keywordPlus | urogenital tract disease | - |
dc.subject.keywordPlus | vasomotor disorder | - |
dc.subject.keywordAuthor | Estrogens | - |
dc.subject.keywordAuthor | Menopause | - |
dc.subject.keywordAuthor | Osteoporosis | - |
dc.subject.keywordAuthor | Urogenital system | - |
dc.subject.keywordAuthor | Vasomotor system | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.